Compounding pharmacies, which specialize in creating customized medications based on individual patient needs, have come under scrutiny in recent years for producing and distributing unapproved and potentially dangerous weight-loss drugs. Several states have started to crack down on these pharmacies, which are often able to avoid regulation by operating outside of the traditional drug manufacturing industry. Compounding pharmacies have long been an important part of the healthcare system, providing specialized medications to patients who require tailored treatment. However, in recent years, some compounding pharmacies have taken advantage of their position to produce and distribute unregulated weight-loss drugs, often marketed as cheaper alternatives to FDA-approved drugs. These knockoff weight-loss drugs are often made using untested and potentially dangerous ingredients, and there have been numerous reports of serious side effects and health complications associated with their use. This has led many states to take action to curb the sale and distribution of these drugs, which are often sold online or through unlicensed distributors. For example, in 2019, the state of Florida passed a law requiring compounding pharmacies to register with the state, and to comply with strict regulations and oversight requirements. The law was prompted in part by a rash of illnesses and deaths linked to a weight-loss drug called 2,4-dinitrophenol (DNP), which had been distributed by unregulated compounding pharmacies. Similarly, in 2021, the state of New York passed a law requiring compounding pharmacies to obtain licenses from the state's Board of Pharmacy, and to comply with regulations and standards similar to those required of traditional drug manufacturers. The law was prompted by concerns over the sale and distribution of unapproved weight-loss drugs, as well as other unregulated medications. Other states, including California and Texas, have also taken steps to regulate compounding pharmacies in order to prevent the sale of unapproved weight-loss drugs. These efforts are part of a broader trend towards increased regulation and oversight of the compounding pharmacy industry, which has been plagued by a lack of transparency and accountability. One of the challenges in regulating compounding pharmacies is that they often operate outside of the traditional drug manufacturing industry, and are subject to different rules and regulations. Compounding pharmacies are able to create customized medications based on individual patient needs, which can be a valuable service for patients with unique medical needs. However, this also means that compounding pharmacies are not subject to the same level of scrutiny and oversight as traditional drug manufacturers, which are required to undergo rigorous testing and review processes before their products can be approved for sale. Compounding pharmacies also face less stringent labeling requirements, which can make it difficult for consumers to know exactly what they are getting when they purchase medications from these pharmacies. This lack of transparency can be particularly concerning when it comes to weight-loss drugs, which are often marketed using misleading or exaggerated claims. In order to address these concerns, states have taken a variety of approaches to regulating compounding pharmacies. Some have focused on increasing transparency and accountability by requiring compounding pharmacies to register with the state, or to obtain licenses from the state's Board of Pharmacy. Others have taken a more aggressive approach, cracking down on unlicensed distributors and illegal online pharmacies that sell unapproved weight-loss drugs. Despite these efforts, however, the problem of unapproved weight-loss drugs continues to be a concern for public health officials. The rise of online pharmacies and unregulated distributors has made it easier than ever for consumers to access potentially dangerous medications, and it can be difficult for regulators to keep up with these rapidly evolving trends. To address this challenge, some experts have called for a more coordinated and comprehensive approach to regulating the compounding pharmacy industry. This could include increased funding for regulatory agencies, as well as greater collaboration between state and federal regulators to ensure that compounding pharmacies are held to the same standards as traditional drug manufacturers.